Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Fang-Shu Ou"'
Autor:
Kabir Mody, Amit Mahipal, Mitesh J. Borad, Lewis R. Roberts, Aminah Jatoi, Gregory J. Gores, Joseph J. Larson, Sumera Ilyas, Wen Wee Ma, Jennifer Gile, Thorvardur R. Halfdanarson, Rory L. Smoot, Robert R. McWilliams, Nguyen H Tran, Steven R. Alberts, Joleen M. Hubbard, Zhaohui Jin, Tanios Bekaii-Saab, Fang-Shu Ou
Publikováno v:
JCO Precis Oncol
PURPOSE Cholangiocarcinomas (CCA) are a group of heterogeneous tumors arising from the biliary epithelia. Significant sequencing efforts have provided further insights into the molecular mechanisms of this disease including fibroblast growth factor r
Autor:
Anne M. Noonan, Jeffrey A. Meyerhardt, Erin Twohy, Tanios Bekaii-Saab, Nathan Hall, Briant Fruth, Paul J. Thurmes, David H. Ilson, Fang-Shu Ou, Alan P. Venook, Daniel J. Boffa, Yelena Y. Janjigian, Donna Niedzwiecki, Eileen M. O'Reilly, Karyn A. Goodman, Wendy L. Frankel, Michael O. Meyers, Kisha Mitchell
Publikováno v:
J Clin Oncol
PURPOSE To evaluate the use of early assessment of chemotherapy responsiveness by positron emission tomography (PET) imaging to tailor therapy in patients with esophageal and esophagogastric junction adenocarcinoma. METHODS After baseline PET, patien
Autor:
Fang-Shu Ou, Tsung Teh Wu, Brenda Ginos, Harry H. Yoon, Timothy F. Drevyanko, Steven R. Alberts, Maged F. Khalil, Gamini S. Soori, Robert J. Behrens, Dennis A. Wigle, Stephen J. Ko, Daniel A. Nikcevich, Robert C. Miller, George P. Kim, Qian Shi, James L. Leenstra, Patrick J. Peller, Robert P. Sticca, Erica N. Heying, Bassam I. Mattar
Publikováno v:
Eur J Cancer
Aim report primary results from the first multicentre randomised trial evaluating induction chemotherapy prior to trimodality therapy in patients with oesophageal or gastro-oesophageal junction adenocarcinoma. Notably, recent data from a single-insti
Publikováno v:
J Thorac Oncol
Biomarkers have various applications including disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. In this era of precision medicine, having validated biomarkers to inform clinical decision making
Autor:
Tanios Bekaii-Saab, Daniel H. Ahn, Erica N. Heying, Patrick McKay Boland, Axel Grothey, Afsaneh Barzi, James M. Cleary, Fang-Shu Ou, Kristen K. Ciombor, Aminah Jatoi, Tyler Zemla, Jeannine S. McCune, Jeff A. Sloan, Boris Pasche, Katrina S. Pedersen, E. Gabriela Chiorean, Nisha L. Jacobs, Heinz-Josef Lenz, Mario E. Lacouture, Jennifer Le-Rademacher
Publikováno v:
Oncologist
Background Hand-foot skin reaction (HFSR) is the most common regorafenib-induced adverse event and is in need of effective prevention and palliation. Materials and Methods The Regorafenib Dose Optimization Study (ReDOS), a four-arm, previously publis
Publikováno v:
J Thorac Oncol
Statistical methods are essential in medical research. They are used for data analysis and drawing appropriate conclusions. Clarity and accuracy of statistical reporting in medical journals can enhance readers' understanding of the research conducted
Publikováno v:
JCO Precision Oncology. :1-10
With the launch of the National Cancer Institute’s Precision Medicine Initiative in 2015, there has been a shift to trial designs that tailor health care solutions to individual patients by using a screening platform and by moving away from the one
Autor:
Kimmie Ng, Charles D. Blanke, Robert J. Mayer, Eileen M. O'Reilly, Brendan J. Guercio, Kaori Sato, Jeffrey A. Meyerhardt, Bert H. O'Neil, Alan P. Venook, Fang-Shu Ou, Howard S. Hochster, Sui Zhang, James N. Atkins, Blase N. Polite, Richard M. Goldberg, Erin L. Van Blarigan, Charles S. Fuchs, Donna Niedzwiecki, James Edward Shaw, Federico Innocenti, Heinz-Josef Lenz
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 29
PURPOSE Regular physical activity is associated with reduced risk of recurrence and mortality in patients with nonmetastatic colorectal cancer. Its influence on patients with advanced/metastatic colorectal cancer (mCRC) has been largely unexplored. P
Autor:
Qian Shi, Jeffrey A. Meyerhardt, Mitchell C. Posner, Vikram Deshpande, Douglas B. Evans, Laura W. Goff, Nipun B. Merchant, Eileen M. O'Reilly, Xiomara W. Carrero, Hedy L. Kindler, Peter W.T. Pisters, Malcolm J. Moore, Elliot Newman, Alice C. Wei, Joseph Misdraji, Jordan Berlin, Fang-Shu Ou, Eric P. Tamm, Dushyant V. Sahani, Robert A. Wolff
Publikováno v:
Ann Surg Oncol
BACKGROUND: There is considerable interest in a neoadjuvant approach for resectable pancreatic ductal adenocarcinoma (PDAC). This study evaluated perioperative gemcitabine + erlotinib (G+E) for resectable PDAC. METHODS: A multicenter, cooperative gro
Autor:
James M. Cleary, E. Gabriela Chiorean, Patrick McKay Boland, Tanios Bekaii-Saab, Daniel H. Ahn, Mario E. Lacouture, Axel Grothey, Nisha L. Jacobs, Jeffrey P. Meyers, Jeannine S. McCune, Jeff A. Sloan, Afsaneh Barzi, Rodwige J. Desnoyers, Erica N. Heying, Heinz-Josef Lenz, Travis J. Dockter, Boris Pasche, Katrina S. Pedersen, Fang-Shu Ou, Kristen K. Ciombor
Publikováno v:
The Lancet Oncology. 20:1070-1082
Summary Background Regorafenib confers an overall survival benefit in patients with refractory metastatic colorectal cancer; however, the adverse event profile of regorafenib has limited its use. Despite no supportive evidence, various dosing schedul